先聲藥業(02096.HK)與IDORSIA就失眠症藥物DARIDOREXANT訂立獨家授權協議

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)與IDORSIA就失眠症藥物DARIDOREXANT訂立獨家授權協議

格隆匯 11-16 07:06

格隆匯11月16日丨先聲藥業(02096.HK)發佈公吿，集團與Idorsia Pharmaceuticals Ltd.於2022年11月15日就失眠症藥物Daridorexant訂立獨家授權協議。根據該協議，集團將獲授該產品在大中華地區的開發及商業化的獨家權利。Idorsia將收取3000萬美元的首付款，並在獲國家藥品監督管理局的監管批准後將有資格收取2000萬美元的額外里程碑付款，及商業化里程碑付款以及基於未來銷售額的低雙位數百分比分級特許權使用費。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)與IDORSIA就失眠症藥物DARIDOREXANT訂立獨家授權協議

Services

About Us

Agreement Statement